Real-world cohort evaluation of the impact of the antifibrotics in patients with idiopathic pulmonary fibrosis

TM Dempsey, V Thao, DA Helfinstine… - European …, 2023 - Eur Respiratory Soc
Extract The antifibrotic medications pirfenidone and nintedanib became the first US Food
and Drug Administration (FDA)-approved medical therapy for the treatment of idiopathic …
被引用次数：4 相关文章

[引用][C] Real-world cohort evaluation of the impact of the antifibrotics in patients with idiopathic pulmonary fibrosis

TM Dempsey, V Thao… - European …, 2023 - mayoclinic.elsevierpure.com
Real-world cohort evaluation of the impact of the antifibrotics in patients with idiopathic pulmonary
fibrosis — Mayo Clinic Skip to main navigation Skip to search Skip to main content Mayo Clinic …

[引用][C] Real-world cohort evaluation of the impact of the antifibrotics in patients with idiopathic pulmonary fibrosis

TM Dempsey, V Thao… - The European …, 2023 - pubmed.ncbi.nlm.nih.gov
Real-world cohort evaluation of the impact of the antifibrotics in patients with idiopathic
pulmonary fibrosis Real-world cohort evaluation of the impact of the antifibrotics in patients …

[引用][C] Real-world cohort evaluation of the impact of the antifibrotics in patients with idiopathic pulmonary fibrosis.

TM Dempsey, V Thao, DA Helfinstine Jr… - The European …, 2023 - europepmc.org
Real-world cohort evaluation of the impact of the antifibrotics in patients with idiopathic
pulmonary fibrosis. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe …

Real-world cohort evaluation of the impact of the antifibrotics in patients with idiopathic pulmonary fibrosis

TM Dempsey, V Thao, DA Helfinstine… - European …, 2023 - Eur Respiratory Soc
Take home message: Consistent with prior observational studies, the antifibrotic
medications pirfenidone and nintedanib were observed to have a reduced risk of mortality …